-
1دورية أكاديمية
المؤلفون: Tivey, A, Shotton, R, Eyre, TA, Lewis, D, Stanton, L, Allchin, R, Walter, H S, Miall, F, Zhao, R, Santarsieri, A, McCulloch, R, Bishton, M, Beech, A, Willimott, V C, Fowler, N, Bedford, C, Goddard, J, Protheroe, S, Everden, A, Tucker, DL, Wright, J, Dukka, S, Thomson, M, Paneesha, S, Prahladan, M, Hodson, A, Qureshi, I, Koppana, M, Owen, M, Ediriwickrema, K, Marr, H, Wilson, J, Lambert, J, Wrench, D J, Burney, C N, Knott, C, Talbot, G, Gibb, Adam, Lord, A, Jackson, B, Stern, S, Sutton, T, Webb, AC, Wilson, M, Thomas, N, Norman, J, Davies, E, Lowry, L, Maddox, J, Phillips, N, Crosbie, N, Flont, M, Nga, EL, Virchis, A, Guerrero Camacho, R, Swe, W, Pillai, A R, Rees, C, Bailey, J D, Jones, SG, Smith, S, Sharpley, Faye, Hildyard, C, Mohamedbhai, S, Nicholson, T, Moule, S, Chaturvedi, Anshuman, Linton, K
المساهمون: Christie NHS Foundation Trust, Macclesfield, United Kingdom.
العلاقة: https://dx.doi.org/10.1182/bloodadvances.2023011152Test; Tivey A, Shotton R, Eyre TA, Lewis D, Stanton L, Allchin R, et al. Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study. Blood advances. 2023 Dec 21. PubMed PMID: 38127279. Epub 2023/12/21. eng.; http://hdl.handle.net/10541/626834Test; Blood Advances
-
2
المؤلفون: Northend, M., Wilson, W., Osborne, W., Fox, C. P., Davies, A. J., El-Sharkawi, D., Phillips, E. H., Sim, H. W., Sadullah, S., Shah, N., Peng, Y. Y., Qureshi, I., Addada, J., Mora, R. F., Phillips, N., Kuhnl, A., Davies, E., Wrench, D. J., McKay, P., Karpha, I., Cowley, A., Karim, R., Challenor, S., Singh, V., Burton, C., Auer, R., Williams, C., Cunningham, J., Broom, A., Arasaretnam, A., Roddie, C., Menne, T., Townsend, W. M.
المساهمون: Cancer Research UK & UCL Cancer Trials Centre, United Kingdom. Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom. Newcastle upon Tyne Hospitals NHS Foundation trust, Newcastle upon Tyne, United Kingdom. Nottingham University Hospitals, Nottingham, United Kingdom. University of Southampton, Southampton, United Kingdom. Royal Marsden Hospital, Sutton, United Kingdom. Division of Cancer Sciences, University of Manchester and Manchester Cancer Research Centre, Manchester, United Kingdom. London North West Healthcare NHS Trust, Middlesex, United Kingdom. James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, United Kingdom. Norfolk and Norwich University Hospital, Norwich, United Kingdom. St George's University Hospitals NHS Foundation Trust, London, United Kingdom. University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Royal Derby Hospital, Derby, United Kingdom. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. University Hospitals of the North Midlands NHS Trust, Stoke-on-Trent, United Kingdom. King's College Hospital NHS Foundation Trust, London, United Kingdom. Manchester University NHS Foundation Trust, Manchester, United Kingdom. Guy's and St.Thomas' NHS Foundation Trust, London, United Kingdom. Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. The Clatterbridge Cancer Centre, Liverpool, United Kingdom. East Sussex Healthcare NHS Trust, Eastbourne, United Kingdom. Dorset County Hospital NHS Foundation Trust, Dorchester, United Kingdom. Royal Cornwall Hospital Trust, Truro, United Kingdom. Aintree University Hospital, Liverpool, United Kingdom. St James's University Hospital, Leeds, United Kingdom. Bart's Health NHS Trust, United Kingdom. Northumbria Healthcare NHS Foundation Trust, Hexham, United Kingdom. Western General Hospital, Edinburgh, United Kingdom. University Hospitals Sussex NHS Trust, Brighton, United Kingdom. UCL, London, United Kingdom. University College London Hospitals, London, United Kingdom.
العلاقة: https://dx.doi.org/10.1182/bloodadvances.2021005953Test; Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, et al. Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma. Blood Advances. American Society of Hematology; 2022.; http://hdl.handle.net/10541/625079Test; Blood Advances
